reports
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Finan...
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overload in patients with chronic kidney disease scPharmaceuticals to host investor conference call and webcast today, Wednesday, March 19th,...
Tenet Healthcare Corp: 2 directors
Two Directors at Tenet Healthcare Corp sold/gave away 25,525 shares at between 0.000USD and 125.433USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financ...
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025 Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET BURLINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 19, 2025, to discuss the financial results for ...
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Appl...
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease FDA approves scPharmaceuticals’ supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome FUROSCIX is expected to be available for chronic kidney disease patients in April 2025 BURLINGTON, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), ...
scPharmaceuticals Announces Participation in Two Upcoming Investor Con...
scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences BURLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will present at the following upcoming investor conferences: 45th Annual TD Cowen Healthcare Conference: Fireside chat on Wednesday, March 5 at 11:10AM ET.Leerink Partners 2025 Global Healthcare Conference: Corporate pre...
Moody's Ratings assigns Baa3 rating to HCA's senior unsecured revolvin...
Moody's Ratings (Moodys) assigned a Baa3 rating to HCA Inc.'s ("HCA") new $8.0 billion senior unsecured revolving credit facility maturing in 2030. HCA intends to use the revolver for general corporate purposes. The new revolver replaces HCA's senior secured revolving credit facilities -- $4.5 billi...
Moody's Ratings assigns Baa3 rating to HCA's proposed senior unsecured...
Moody's Ratings (Moody's) assigned Baa3 ratings to HCA Inc.'s ("HCA") proposed offering of backed senior unsecured notes of up to $5.25 billion with various maturities. HCA intends to use the net proceeds from this offering for general corporate purposes including repayment of borrowings outstanding...
HCA Healthcare Inc: 1 director
A director at HCA Healthcare Inc sold/sold after exercising options 9,533 shares at 322.589USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's director...
Moody's Ratings assigns Baa3 rating to HCA's proposed senior unsecured...
Moody's Ratings (Moodys) assigned Baa3 ratings to HCA Inc.'s ("HCA") proposed offering of backed senior unsecured notes of up to $5.25 billion with various maturities. HCA intends to use the net proceeds from this offering for general corporate purposes including repayment of borrowings outstanding ...
scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare...
scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference BURLINGTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President & Chief Executive Officer, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12 at 2:40PM ET. A webcast of the presentation can be accessed or under “News & Events” in the Invest...
scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Fu...
scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over Q4 2023 at the mid-point of the range Fourth quarter 2024 Gross-to-net (GTN) discount expected to be in the range of 18% to 19% Preliminary unaudited full year 2024 net revenue expected to be approximately $36.2 million to $36.5 million, compared to $13.6 million for full year 2023 BURLINGTON, Mass., Jan. 10, 2025 (GLOBE N...
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
PEP PEPSICO INC.
ANTM ANTHEM INC.
NUE NUCOR CORPORATION
NXPIN NXP SEMICONDUCTORS NV
CSX CSX CORPORATION
TXT TEXTRON INC.
TX. TERNIUM S.A. SPONSORED ADR
TDG TRANSDIGM GROUP INCORPORATED
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
PII POLARIS INC.
KMB KIMBERLY-CLARK CORPORATION
HCA HCA HEALTHCARE INC
GD GENERAL DYNAMICS CORPORATION
FANG DIAMONDBACK ENERGY INC.
DCI DONALDSON COMPANY INC.
CVS CVS HEALTH CORPORATION
CAL CALERES INC.
CACI CACI INTERNATIONAL INC CLASS A
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
AVAV AEROVIRONMENT INC.
ASH ASHLAND GLOBAL HOLDINGS INC.
AMAT APPLIED MATERIALS INC.
ACGL ARCH CAPITAL GROUP LTD.
AIG AMERICAN INTERNATIONAL GROUP INC.
CNR. CANADIAN NATIONAL RAILWAY COMPANY
TEX TEREX CORPORATION
MEG. MEG ENERGY CORP.
MUR MURPHY OIL CORPORATION
MMC MARSH & MCLENNAN COMPANIES INC.
FRO FERRO S.A.
ITKA ANHEUSER-BUSCH INBEV N.V. ADS
FI FRANK'S INTERNATIONAL NV
GES GUESS? INC.
WFT.. WEATHERFORD INTERNATIONAL PLC
XYL XYLEM INC.
QCOM.. QUALCOMM INC.
AMD ADVANCED MICRO DEVICES INC.
AMEH APOLLO MEDICAL HOLDINGS INC
CI CIGNA CORPORATION
STNG SCORPIO TANKERS INC.
UBER UBER TECHNOLOGIES INC.
RXST RXSIGHT INC
CHRD CHORD ENERGY CORPORATION
TNK FRONTLINE PLC
TEEKAY TANKERS LTD.
scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results an...
scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update Generated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive pharmacokinetic/pharmacodynamic (PK/PD) data on Autoinjector program Completed $125 million transformative financing in a combination of debt and equity that is anticipated to fund the Company through expected profitability Company to host investor conference call and webcast today, Wednesday, N...
scPharmaceuticals to Announce Third Quarter 2024 Financial Results on ...
scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 Management to host conference call and webcast, after-market on November 13, 2024, at 4:30 p.m. ET BURLINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, November 13, 2024, to discuss the financial results for the thi...
- Gary Brode
scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October ...
scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024 Webinar to focus on a nephrologist’s perspective on the use of FUROSCIX for fluid overload in heart failure and potential use in chronic kidney disease BURLINGTON, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it will host a KOL webinar focused on a nephrologis...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
SPX Testing Resistance as Rate Cut Cycle Begins The S&P 500 (SPX) is back to test YTD highs and important resistance in the 5670-5783 range. This is an important target/resistance area we have discussed for weeks; using the 2007 SPX topping analog which has tracked the current market almost perfectly, it would suggest a 2% or less move above the prior all-time high set in July at 5670 before topping, which is where we get the 5783 number. As long as the SPX does not have a weekly close above 57...
UHS UNIVERSAL HEALTH SERVICES INC. CLASS B
THC TENET HEALTHCARE CORPORATION
SGRY SURGERY PARTNERS INC.
SEM SELECT MEDICAL HOLDINGS CORPORATION
PFG PRINCIPAL FINANCIAL GROUP INC.
NDAQ NASDAQ INC.
MKTX MARKETAXESS HOLDINGS INC.
MFC. MANULIFE FINANCIAL CORPORATION
IBKR INTERACTIVE BROKERS GROUP INC. CLASS A
HCA HCA HEALTHCARE INC
CME CME GROUP INC. CLASS A
CBOE CBOE GLOBAL MARKETS INC
PRU PRUDENTIAL FINANCIAL INC.
VIRT VIRTU FINANCIAL INC. CLASS A
MET METLIFE INC.
CYH COMMUNITY HEALTH SYSTEMS INC.
ICE CANLAN ICE SPORTS
SLF SALAFIN
SNEX STONEX GROUP INC
EQH EQUITABLE HOLDINGS INC.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.